Kennedy's controversial claims and proposed actions have negatively impacted pharmaceutical and biotech markets, causing a significant drop in shares. The concerns stem from his stance on vaccines, FDA regulations, and food safety measures, leading to uncertainty and skepticism among investors and analysts.